Advertisement

Klinische Maßnahmen bei imminenter oder geplanter Frühgeburt

  • V. Ragosch

Zusammenfassung

Bei nicht aufzuhaltender oder geplanter Frühgeburt muss es vorrangiges Ziel sein, unreifebedingten Erkrankungen vorzubeugen. An erster Stelle ist an das Atemnotsyndrom zu denken. Die Diagnostik der fetalen Lungenreife hat dabei in den letzten Jahren immer mehr an Bedeutung verloren. Demgegenüber kommt der antenatalen Gabe von Glukokortikoiden eine große Bedeutung zu, die zwischen der 24. und 34. SSW grundsätzlich bei drohender Frühgeburt und ausgeschlossenem Amnioninfektionssyndrom verabreicht werden sollten. Hierdurch kommt es nicht nur zu einer deutlichen Reduktion eines Atemnotsyndroms, sondern es werden auch die intraventrikulären Blutungen und die Mortalität günstig beeinflusst. Nicht unumstritten ist die Applikation mehrerer Zyklen von Glukokortikoiden, die einer strengen Indikation bedarf.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abbasi S, Hirsch D, Davis J, Tolosa J, Stouffer N, Debbs R, Gerdes JS (2000) Effect of single versus multiple course of antenatal corticosteroids an maternal and neonatal outcome. Am J Obstet Gynecol 182: 1243–1249PubMedCrossRefGoogle Scholar
  2. Abdel-Rahman AM, Rosenberg AA (1994) Prevention of intraventricular hemorrhage in the premature infant. Clin Perinatol 21: 505–521PubMedGoogle Scholar
  3. Antenatal Corticosteroids Revisited (2000) Repeated courses. NIH Consensus Statement 2000. intro.htm.Google Scholar
  4. ACOG (1996) Assessment of fetal lung maturity. ACOG Educational Bulletin 230: 1–7Google Scholar
  5. Barkai G, Mashiach S, Reichman B, Modan M, Meir E, Goldman B (1986) Effect of blood contamination an the fluorescence polarization value of amniotic fluid lamellar bodies. Obstet Gynecol 68: 379–381PubMedCrossRefGoogle Scholar
  6. Buyon JP, Waltuck J, Kleinman CS, Copel JA (1995) In uteri identification and therapy of congenital heart block. Lupus 4: 116–121PubMedCrossRefGoogle Scholar
  7. Copel JA, Friedman AH, Kleinman CS (1997) Management of fetal cardiac arrhythmias. Obstetrics and Gynecology Clin North Am 24: 201–211CrossRefGoogle Scholar
  8. Cosmi EV, Di Renzo GC (1989) Assessment of foetal lung maturity. Eur Respir J 1:40s-49sGoogle Scholar
  9. Creasy RK (1993) Preterm birth prevention: where are we?. Am J Obstet Gynecol 168: 1223–1230PubMedGoogle Scholar
  10. Crowley P, Chalmers I, Keirse MJNC (1990) The effect of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 97: 11–25PubMedCrossRefGoogle Scholar
  11. Crowley PA (1995) Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 173: 322–335PubMedCrossRefGoogle Scholar
  12. Crowley P (1999) Prophylactic corticosteroids for preterm delivery (Cochrane review). In: The Cochrane Library, Issue 3. Update Software, OxfordGoogle Scholar
  13. Crowther C, Alfirevic Z, Haslam R (1999) Prenatal thyrotropin-releasing hormone (TRH) for preterm birth (Cochrane review). In: The Cochrane Library, Issue 3. Update Software, OxfordGoogle Scholar
  14. Dalence CR, Bowie LJ, Dohnal JC, Farrell EE, Neerhof MG (1995) Amniotic fluid lamellar body count: a rapid and reliable fetal lung maturity test. Obstet Gynecol 86: 235–239PubMedCrossRefGoogle Scholar
  15. DiFiore JW, Wilson JM (1994) Lung development. Seminars in Pédiatric Surgery 3: 221–232PubMedGoogle Scholar
  16. Dubin SB (1992) Assessment of fetal lung maturity by laboratory methods. Clin Lab Med 12: 603–620PubMedGoogle Scholar
  17. Entezami M, Becker R (1995) Fetaler Thorax. In: Becker R, Fuhrmann W, Holzgreve W, Sperling K (Hrsg) Pränatale Diagnostik und Therapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 157–164Google Scholar
  18. French NP, Hagan R, Evans SF, Godrey M, Newham JP (1999) Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 180: 114–121PubMedCrossRefGoogle Scholar
  19. Gardner MO, Papile LA, Wright LL (1997) Antenatal corticosteroids in pregnancies complicated by preterm premature rupture of membranes. Obstet Gynecol 90: 555–564CrossRefGoogle Scholar
  20. Gembruch U, Manz M, Bald R, Ruddel H, Redel DA, Schlebusch H, Nitsch J, Hansmann M (1989) Repeated intracascular treatment with amiodarone in a fetus with refractory supraventricular tachycardia and hydrops fetalis. Am Heart J 118: 1335–38PubMedCrossRefGoogle Scholar
  21. Gluck L, Kulovich MV, Borer RC, Brenner PH, Anderson GG, Spellacy WN (1971) Diagnosis of the respiratory distress syndrome by amniocentesis. Am J Obstet Gynecol 109: 440–445PubMedGoogle Scholar
  22. Grether JK, Nelson KB, Emery ES 3rd, Cummins SK (1996) Prenatal and perinatal factors and cerebral palsy in very low birth weight infants. J Pediatr 128: 407–414PubMedCrossRefGoogle Scholar
  23. Guinn DA, Atkinson MW, Sullivan L et al. (2001) Single vs. weekly courses of antenatal corticosteroids for women at risk of preterm delivery. JAMA 286: 1581–1587PubMedCrossRefGoogle Scholar
  24. Hallman M, Feldman BH, Kirkpatrick E, Gluck L (1977) Absence of phosphatidylglycerol (PG) in respiratory distress syndrome in the newborn. Study of the minor surfactant phospholipids in newborns. Pediatr Res 11: 714–720PubMedCrossRefGoogle Scholar
  25. Harding, JE, Pank J, Knight DB, Liggins GC (2001) D antenatal corticosteroids help in the setting of preterm rupture of membranes?. Am J Obstet Gynecol, 184: 131–139PubMedCrossRefGoogle Scholar
  26. Hentschel J, Arlettaz R, Biihrer C (2001) Überlebenschancen und Langzeitprognose bei Geburt in der Grauzone der Lebensfähigkeit. Gynäkologe 34: 697–707CrossRefGoogle Scholar
  27. Hildebrandt A (1992) Bekanntmachung überdie Zulassung und Registrierung von Arzneimitteln. Monographie Ambroxol. G VII 7460-00-4747/92Google Scholar
  28. Hildebrandt R, Ragosch V (1994) Interaktion von Tokolyse und fetaler Lungenreifung. In: Wolff z (Hrsg) Standortbestimmung derTokolysebehandlung. Steinkopf, DarmstadtGoogle Scholar
  29. Hueston WJ (1998) Preterm contractions in community settings: I.Treatment of preterm contractions. Obstet Gynecol 92: 38–43PubMedCrossRefGoogle Scholar
  30. Kleinman CS, Copel JA (1996) Fetal arrhythmias in ultrasound and the fetal heart. In: Wladimiroff JW, Pilu G (eds) Progress in obstetric and gynecological sonography series. Parthenon, London, p 93Google Scholar
  31. Lewis DF, Futayyeh S, Towers CV, Asrat T, Edwards S, Brooks GG (1996) Preterm delivery from 34 to 37 weeks of gestation: is respiratory distress syndrome a problem?. Am J Obstet Gyncol 174: 525–528CrossRefGoogle Scholar
  32. Liggins GC, Howie RN (1972) A controlled trial of ante, partum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50: 515–525PubMedGoogle Scholar
  33. Lorenz U, Ragosch V, Weitzel H (1990) Diagnostik der fetalen Lungenreife. Gynäkologe 23: 284–288PubMedGoogle Scholar
  34. Lucey J, Soll R, Hörbar J (1991) Vermont-Oxford Trial Network, 52 Overlake Park, Burlington, VT 05401Google Scholar
  35. Luerti M, Lazzarin A, Corbella E Zavattini G (1987) Alternative to steroids for prevention of respiratory distress syndrome (RDS): multicenter controlled study to compare ambroxol and betamethasone. J Perinat Med 15: 227–238PubMedCrossRefGoogle Scholar
  36. MacArthur BA, Howie RN, Dezoete JA, Elkins J (1982) School progress and cognitive development of 6-year old children whose mothers were treated antenatally with betamethasone. Pediatrics 70: 99105Google Scholar
  37. Moya FR, Groß I (1993) Combined hormonal therapy or the prevention of respiratory distress syndrome and its consequences. Semin Perinatol 17: 67–274Google Scholar
  38. Neu J (1996) Necrotizing enterocolitis.The search for a unifying pathogenic therapy leading to prevention. Pediatr Clin North Am 2: 409–432CrossRefGoogle Scholar
  39. NIH Consensus Conference (1995) Effect of corticosteroids for fetal maturation an perinatal outcomes. JAMA 273: 413–418CrossRefGoogle Scholar
  40. Ragosch V, Hundertmark S, Fuhr N, Hopp H, Weitzel 11 (1995) Management des frühen vorzeitigen Blasensprungs an geburtshilflichen Abteilungen in Deutschland. Z Geburtshilfe Neonatol 199: 236–242PubMedGoogle Scholar
  41. Ragosch V, Weitzel H (1995) Derzeitiger Stand der Lungenreifeinduktion zur Vermeidung eines neonatalen Atemnotsyndroms. Gynäkologe 28: 203–210PubMedGoogle Scholar
  42. Ragosch V (1997) Fetale Lungenreife: Klinische Untersuchungen zu diagnostischen Methoden und tierexperimentelle Untersuchungen zur pharmakologischen Beeinflussung. HabilitationsschriftGoogle Scholar
  43. Ragosch V, Dudenhausen W, Gräuel L, Schneider KTM, Vetter K, Weitzel H (2000) Empfehlungen zum Vorgehen beim vorzeitigen Blasensprung. Frauenarzt 41: 271–272Google Scholar
  44. Salzer H, Weidinger H, Simbruner G, Vytiska-Binstorfer E (1986) Ambroxol versus Betamethason zur Förderung der antepartalen Lungenreife — eine multizentrische Studie. Z Geburtsh Periat 190: 49–59Google Scholar
  45. Schmidt KG, Ulmer HE, Silverman NH, Kleinman CS, Copel JA (1991) Perinatal outcome of fetal complete atrioventricular block: A multicenter experience. J Am Coll Cardio 191: 1360–66CrossRefGoogle Scholar
  46. Smolders-de Haas H, Neuvel J, Schmand B, Treffers PE, Koppe JG, Hoeks J (1990) Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10-to 12-year follow up. Pediatrics 86: 65–70PubMedGoogle Scholar
  47. Stigson L, Kjellmer I (1997) Serum levels of magnesium at birth related to complications of immaturity. Acta Paediatr 86: 991–994PubMedCrossRefGoogle Scholar
  48. Thorp JA, Parriott J, Ferrette-Smith D, Meyer BA, Cohen GR, Johnson J (1994) Antepartum vitamin k and phénobarbital for preventing intraventricular hemorrhage in the premature newborn: a randomized, double-blind, placebo-controlled trial. Obstet Gynecol 83: 70–76PubMedGoogle Scholar
  49. Vermillion ST, Soper DE, Chasedunn RJ (1999) Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Am J Obstet Gynecol 181: 320–327PubMedCrossRefGoogle Scholar
  50. Wauer RR, Schmalisch G, Menzel K et al. (1982) The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study. Biol Res Preg 3: 84–91Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • V. Ragosch

There are no affiliations available

Personalised recommendations